web analytics
0.4 C
Munich
Saturday, December 3, 2022

Cannabis Science Inc (OTCMKTS:CBIS) Testing Support Levels

Cannabis Science Inc (OTCMKTS:CBIS) is currently testing the $0.06 support levels. The stock has continued to slide further down in recent months since topping out at $0.1395 earlier this year. CBIS is one of the original Marijuana plays to hit the BB’s back in 2009. Over the past several years as Marijuana stocks have heated up CBIS has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs.

CBIS is at the right place at the right time; pot stocks have heated up going into the election and following Trumps upset. The red hot Marijuana industry has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states legalizing the drug including California, Nevada, Maine, and Massachusetts on November 8. Medical MJ products in the U.S. alone are projected to generate up to $35 Billion by 2020.

Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.

CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:

The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”

The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”

To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.

The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.

CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.

On May 11 CBIS announced the release of a limited batch of cannabinoid-based suppositories for self-medicating, male and female patients. The suppositories aid with symptoms related to cancer, anxiety, insomnia, and severe pain relief. This Unisex Suppository Regimen Package, consisting of rectal suppositories, is the first of three regimen packages that will be released by CBIS to address the tremendous demand for cannabinoid-based medicines for self-medicating patients who require alternative delivery methods.

Suppositories are 50% to 70% more efficient and produce a more predictable effect than smoked or ingested cannabis. The rectal endothelium provides greater bioavailability than transcutaneous and oral delivery of cannabinoids. Suppositories can also be more effective in treating pelvic and lower gastrointestinal conditions. Additionally, suppositories are effective in individuals with nausea and vomiting, those with difficulty in swallowing pills (the elderly), those with wasting conditions especially in cases where appetite is inhibited, and in individuals on chemotherapy who find it difficult to manage oral medications.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $149 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is currently testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. CBIS is one of the original pot stocks with a long history of making spectacular 2000% plus moves that knows how to get its story into the national media. CBIS is a great place to be when pot stocks heat up as they are right now leading up to November 8. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.